SCHEMBL221825

SCHEMBL221825

Cc1c[nH]c(=O)n(C)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 1/20 0.41
ATAD2 Q6PL18 2/20 0.38
ADORA2A P29274 2/20 0.37
ADORA2B P29275 2/20 0.37
ADORA3 P0DMS8 1/20 0.35
ADORA1 P30542 1/20 0.35
CYP3A4 P08684 2/20 0.33
ALDH1A1 P00352 2/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
TSHR P16473 1/20 0.33
BLM P54132 1/20 0.33
PMP22 Q01453 1/20 0.33
BRPF1 P55201 1/20 0.32
CRBN Q96SW2 1/20 0.32
ADRA1A P35348 4/20 0.32
ADRA1B P35368 4/20 0.32
ADRA1D P25100 3/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6561465 0.75
SCHEMBL17490535 0.74 SLC9A1 (0.44) SLC9A1ATAD2ALDH1A1NOTUMKDM4E
SCHEMBL22107468 0.74 SLC9A1 (0.40) SLC9A1ATAD2NOTUM
SCHEMBL15031427 0.74 SLC9A1 (0.40) SLC9A1ATAD2NOTUM
SCHEMBL7141528 0.74 SLC9A1 (0.40) SLC9A1ATAD2NOTUM
SCHEMBL24712473 0.74 SLC9A1 (0.40) SLC9A1ATAD2NOTUM
SCHEMBL15663365 0.74 SLC9A1 (0.40) SLC9A1ATAD2NOTUM
SCHEMBL16652006 0.74 ADORA2A (0.36) ADORA2AADORA2BADORA3ADORA1CYP3A4
SCHEMBL2078821 0.74 ADORA2A (0.36) ADORA2AADORA2BADORA3ADORA1CYP3A4
SCHEMBL9685966 0.74 ALDH1A1 (0.37) ADORA2AADORA2BADORA3ADORA1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119381591-A Zinc metal self-repairing high-performance fibrous flexible water-based zinc battery and preparation method thereof 中国电子科技集团公司第十八研究所 2025-01-28 CN claimed
EP-4357461-A2 DETERMINATION OF BASE MODIFICATIONS OF NUCLEIC ACIDS The Chinese University Of Hong Kong (CN) 2024-04-24 EP claimed
EP-3827092-B1 DETECTION OF METHYLATION OF NUCLEOTIDES IN NUCLEIC ACIDS UNIV HONG KONG CHINESE (CN) 2024-01-31 EP claimed
CN-112752853-B Determination of base modification of nucleic acids 香港中文大学 2023-06-30 CN claimed
CN-115508408-A Method for rapidly determining concentration of 6-amino 1,3 dimethyl uracil by differential scanning calorimetry 慧科高新科技股份有限公司 2022-12-23 CN claimed
EP-3827092-A1 DETERMINATION OF BASE MODIFICATIONS OF NUCLEIC ACIDS The Chinese University Of Hong Kong (CN) 2021-06-02 EP claimed
CN-112752853-A Determination of base modifications of nucleic acids 香港中文大学 2021-05-04 CN claimed
WO-2021032060-A1 DETERMINATION OF BASE MODIFICATIONS OF NUCLEIC ACIDS THE CHINESE UNIVERSITY OF HONG KONG (CN) 2021-02-25 WO claimed
CN-106046004-B A kind of total synthesis method of 1,3,7,9- tetramethyluric acids 上海佰特因医药科技有限公司 2018-05-15 CN claimed
EP-3157573-A2 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF Moderna Therapeutics, Inc. (US) 2017-04-26 EP claimed
CN-1349133-A Developer solution for silver salt diffusing and transferring aluminium-base offset plate and its use INST OF PHOTOCHEMISTRY CHINESE (CN) 2002-05-15 CN claimed
US-20020055506-A1 Methods for treatment of disease-induced peripheral neuropathy and related conditions SPECTRUM PHARMACEUTICALS, INC. 2002-05-09 US claimed
US-20020040031-A1 Methods for prevention of accumulation of amyloid beta peptide in the central nervous system NEO THERAPEUTICS, INC. 2002-04-04 US claimed
US-20020040032-A1 Methods for stimulation of synthesis of synaptophysin in the central nervous system NEOTHERAPEUTICS, INC. 2002-04-04 US claimed
WO-2002004450-A2 METHODS FOR PREVENTION OF ACCUMULATION OF AMYLOID BETA PEPTIDE IN THE CENTRAL NERVOUS SYSTEM NEOTHERAPEUTICS, INC. (US) 2002-01-17 WO claimed
WO-2002004452-A2 METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS NEOTHERAPEUTICS, INC. (US) 2002-01-17 WO claimed
WO-2002004449-A2 METHODS FOR TREATMENT OF CONDITIONS AFFECTED BY ACTIVITY OF MULTIDRUG TRANSPORTERS NEOTHERAPEUTICS, INC. (US) 2002-01-17 WO claimed
WO-2002004451-A2 METHODS FOR STIMULATION OF SYNTHESIS OF SYNAPTOPHYSIN IN THE CENTRAL NERVOUS SYSTEM NEOTHERAPEUTICS, INC. (US) 2002-01-17 WO claimed
WO-2002004448-A2 METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS NEOTHERAPEUTICS, INC. (US) 2002-01-17 WO claimed
WO-1994015622-A1 NUCLEOSIDE DERIVATIVES AND THEIR USE AS EXCITATORY AMINO ACID ANTAGONISTS CAMBRIDGE NEUROSCIENCE (US) 1994-07-21 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055506-A1 Methods for treatment of disease-induced peripheral neuropathy and related conditions NGF, NUDT1, HPRT1 SLC9A1 3214/4885ATAD2 4545/4885ADORA2A 241/4885
US-20020040032-A1 Methods for stimulation of synthesis of synaptophysin in the central nervous system GAP43, BDNF, APP SLC9A1 2454/4885ATAD2 3944/4885ADORA2A 235/4885
US-20020040031-A1 Methods for prevention of accumulation of amyloid beta peptide in the central nervous system APP, BACE1, SARNP SLC9A1 3159/4885ATAD2 2203/4885ADORA2A 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.